Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis
about
The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility studyDecline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinomaDocetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.MALDI-TOF Mass Array Analysis of Nell-1 Promoter Methylation Patterns in Human Gastric CancerComparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 triImpact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancerAnthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.Chemotherapy for advanced gastric cancer.miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center.
P2860
Q27318805-BF51D6D0-5B42-4AE6-92A3-77B587CDBD28Q33418948-9A114C7B-BA64-4115-988C-336C96038EAFQ34130176-8DDFDE45-3E0C-4BC1-B6BC-7E47937CCE15Q34658209-0B9E8B43-10B5-4541-B623-85AF6BDD8C60Q35070531-23709CE4-1C03-448C-B2B8-6D1D9877825FQ35668216-F0489EB4-DECD-4824-8E5C-11C751D634EBQ36042902-CAB8F687-D2FD-4090-A5F8-2C7BA18B367CQ36085937-A367182E-F315-4EA1-BD8E-92178EAC715AQ36341670-C8D31157-DB53-4827-87DE-AF734D5A52ADQ36396339-FAEC0DC9-71E7-45D7-8307-1E592785F985Q38604012-8DE331A7-C1EC-4F76-8CEB-3AAB7E30B1EAQ39091716-2C2FAFBE-5161-448B-928B-48196EE6B03DQ45218658-4281794F-4A4A-45CB-B60A-1BDFF35E1F06
P2860
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@ast
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@en
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@nl
type
label
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@ast
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@en
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@nl
prefLabel
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@ast
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@en
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P921
P1433
P1476
Docetaxel, cisplatin and fluor ...... matic review and meta-analysis
@en
P2093
Jia-Ping Chen
Jian-Kun Hu
Xiao-Long Chen
Xin-Zu Chen
P2860
P304
P356
10.1371/JOURNAL.PONE.0060320
P407
P5008
P577
2013-04-04T00:00:00Z